JPMorgan Chase & Co. Raises Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $106.00

Protagonist Therapeutics (NASDAQ:PTGX) had its target price boosted by JPMorgan Chase & Co. from $95.00 to $106.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 7.21% from the company’s previous close.

PTGX has been the topic of a number of other reports. HC Wainwright boosted their target price on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, January 30th. TD Cowen raised their price target on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $121.00 price target on shares of Protagonist Therapeutics in a report on Wednesday. The Goldman Sachs Group upped their price objective on Protagonist Therapeutics from $65.00 to $95.00 and gave the company a “neutral” rating in a research note on Tuesday, March 3rd. Finally, Barclays increased their price objective on Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a report on Thursday. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.31.

Protagonist Therapeutics Price Performance

NASDAQ PTGX opened at $98.87 on Thursday. The business’s fifty day moving average is $87.17 and its 200-day moving average is $80.87. The stock has a market capitalization of $6.31 billion, a price-to-earnings ratio of -48.23 and a beta of 2.23. Protagonist Therapeutics has a one year low of $39.60 and a one year high of $105.69.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. The company had revenue of $7.44 million for the quarter, compared to the consensus estimate of $14.92 million. Research analysts expect that Protagonist Therapeutics will post 2.43 EPS for the current fiscal year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 4,068 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $83.19, for a total value of $338,416.92. Following the sale, the chief executive officer directly owned 574,505 shares in the company, valued at $47,793,070.95. This represents a 0.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Arturo Md Molina sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $82.00, for a total transaction of $410,000.00. Following the completion of the transaction, the insider directly owned 84,115 shares of the company’s stock, valued at approximately $6,897,430. The trade was a 5.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 203,167 shares of company stock worth $16,889,199 in the last ninety days. Insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. American Century Companies Inc. raised its holdings in shares of Protagonist Therapeutics by 18.7% in the 2nd quarter. American Century Companies Inc. now owns 813,995 shares of the company’s stock valued at $44,990,000 after acquiring an additional 128,171 shares in the last quarter. Voya Investment Management LLC boosted its position in shares of Protagonist Therapeutics by 8.9% during the 3rd quarter. Voya Investment Management LLC now owns 305,419 shares of the company’s stock valued at $20,289,000 after acquiring an additional 25,065 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new position in shares of Protagonist Therapeutics during the second quarter worth about $6,641,000. Creative Planning increased its position in shares of Protagonist Therapeutics by 74.3% in the second quarter. Creative Planning now owns 30,204 shares of the company’s stock worth $1,669,000 after purchasing an additional 12,871 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Protagonist Therapeutics by 2,043.8% in the third quarter. SG Americas Securities LLC now owns 41,246 shares of the company’s stock worth $2,740,000 after purchasing an additional 39,322 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Key Headlines Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval of J&J’s Icotyde for plaque psoriasis materially improves Protagonist’s near-term commercial outlook by triggering milestone payments and future royalty upside tied to Protagonist’s partnered program. Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here’s Why
• Positive Sentiment: Market reaction: coverage highlights a ~6–7% lift tied to the approval and notes the path to royalties; higher-than-average volume suggests institutional interest and re-rating momentum. Why Protagonist Therapeutics (PTGX) Is Up 6.6% After First Psoriasis Drug Wins FDA Approval
• Positive Sentiment: Several major banks raised price targets and reiterated buy/overweight ratings following the approval, providing further upside expectations (Leerink, JPMorgan, Citigroup, Barclays). These analyst upgrades are supporting the stock’s recent run. Analyst coverage roundup (Benzinga) JPMorgan note (TickerReport) Citigroup coverage (Zacks)
• Positive Sentiment: Zacks notes recent momentum and that recent earnings-estimate revisions could support further upside in the near term. Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
• Neutral Sentiment: Broader Wall Street commentary emphasizes that J&J’s approval should create “significant value” for Protagonist, reinforcing sentiment but not guaranteeing cash flow until milestones/royalties are realized. Wall Street says J&J’s FDA-approved psoriasis drug should create significant value for Protagonist
• Negative Sentiment: Key risk: Protagonist reported an earnings and revenue miss in its last report and remains unprofitable with negative margins—meaning the market is pricing future milestone/royalty potential rather than current cash generation. This raises execution and timing risk (milestones may be delayed or smaller than expected).

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.